Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospices Civils de Lyon
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients \>= 18 years old
Patients with colon or rectal carcinoma histologically proven
Patients with metastases (synchronous or metachronous)
Patients with associated extra-hepatic disease (asymptomatic primary tumor or extra-hepatic metastases)
Performance status (World Health Organization \[WHO\]) = 0, 1, or 2
Life expectancy \>= 3 months
Patients with normal haematological, kidney, and liver parameters (PNN \> 1.5 x 10\^9/L, platelets \> 100 10\^9/L, total bilirubin \<= 1.25 x upper limit of normal (ULN), ASAT/ALAT \<= 5 x ULN, creatinaemia \<= 135 µmol/L (1.5 mg/dL)
No cardiac or coronary insufficiency untreated
At least 4 weeks between surgery and study beginning
Patients can have a biopsy of the hepatic lesion identified by ultrasound.
Informed consent signed.
You may not be if
Patients with symptomatic tumors (colon or rectal)
Patients with others tumors not cured
Patients who cannot be treated by 5-fluorouracil (5-FU) and/or irinotecan because of special medical conditions or other serious disease.
Patients who participated in another clinical trial since less than 30 days
Pregnancy or breast-feeding women
Patients who cannot be treated because of active infection or other serious disease.
Clareo Health | Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
